{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-007815","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.405456+00:00","generated_at":"2026-06-08T06:39:39.670330+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio Pharma Q3 net loss narrows to $2.8M; first patient dosed in PH-762 Phase 1b trial","bullets":["Q3 net loss $2.8M ($1.14/sh) vs $3.6M ($3.14/sh) in Q3 2022; cash at Sep 30 $8.4M down from $11.8M at Dec 31 2022.","R&D expenses fell 28% YoY to $1.8M; G&A fell 9% to $1.0M.","First patient dosed in U.S. Phase 1b trial of intratumoral PH-762 (anti-PD-1) for skin carcinomas (NCT06014086).","Trial expected to enroll up to 30 patients across 4-6 U.S. sites; neoadjuvant monotherapy with dose escalation.","Company presented preclinical data on PH-894 (BRD4) and CTLA-4-targeting INTASYL at recent conferences."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-007815","json":"https://secwatch.observer/filing/0001683168-23-007815.json","markdown":"https://secwatch.observer/filing/0001683168-23-007815.md","text":"https://secwatch.observer/filing/0001683168-23-007815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823007815/0001683168-23-007815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823007815/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:39:39.670330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4680a93a77fca6a7d95c29b69e947b67f9e9c4f3","claim":"Phio Pharmaceuticals Corp. reported the quarter ended September 30, 2023 results: net income Net loss was $2.8 million, or $1.14 per share.","evidence_excerpt":"Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the period ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823007815/0001683168-23-007815-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $2.8 million, or $1.14 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}